Evaluation of glycopeptide use in nine French hospitals;Évaluation de l'utilisation des glycopeptides dans neuf hôpitaux français.

Medecine et Maladies Infectieuses

Volumn 40, Issue 4, 2010, Pages 232-237

  Alfandari, S ^a   Levent, T ^b   Descamps, D ^c   Hendricx, S ^c   Bonenfant, C ^c   Taines, V ^d   Cattoen, C ^e   Arimane, O ^f   Grandbastien, B ^g  

^a CENTRE HOSPITALIER DE TOURCOING   (France)

^b Cntre hospitalier   (France)

^c CENTRE HOSPITALIER   (France)

^d Plyclinique du Bois ^*  (France)

^e CENTRE HOSPITALIER DE VALENCIENNES   (France)

^f EOH   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antibacterial agents; Glycopeptides; Quality of health care; Staphylococci

Indexed keywords

GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG SCREENING; DRUG USE; ENDOCARDITIS; FRANCE; HEALTH CARE QUALITY; HOSPITAL CARE; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OSTEOARTHROPATHY; PENICILLIN RESISTANCE; PHYSICIAN ATTITUDE; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PSEUDOMEMBRANOUS COLITIS; SEPSIS; SKIN INFECTION; TREATMENT INDICATION; URINARY TRACT INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG PRESCRIPTIONS; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION REVIEW; FRANCE; GUIDELINE ADHERENCE; HOSPITALS; HOSPITALS, PRIVATE; HOSPITALS, PUBLIC; HOSPITALS, UNIVERSITY; HUMANS; INFUSIONS, INTRAVENOUS; PROSPECTIVE STUDIES; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 77952292053     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2009.10.019     Document Type: Article

References (35)

1. O'Brien T.F. Emergence, spread, and environmental effect of antimicrobial resistance: how use of an antimicrobial anywhere can increase resistance to any antimicrobial anywhere else. Clin Infect Dis 2002, 34(Suppl. 3):S78-S84. 10.1086/340244.
2. Jones M.E., Draghi D.C., Thornsberry C., Karlowsky J.A., Sahm D.F., Wenzel R.P. Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004, 3:14. 10.1186/1476-0711-3-14.
3. Howden B.P., Ward P.B., Charles P.G., Korman T.M., Fuller A., du Cros P., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
4. Naas T., Fortineau N., Snanoudj R., Spicq C., Durrbach A., Nordmann P. First nosocomial outbreak of vancomycin-resistant Enterococcus faecium expressing a VanD-like phenotype associated with a vanA genotype. J Clin Microbiol 2005, 43:3642-3649. 10.1128/JCM.43.8.3642-3649.2005.
5. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98. 10.2146/ajhp080434.
6. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995; 44:1-13.
7. Bingen E., Mariani-Kurkdjian P., Nebbad B. Comment optimiser le taux sérique de vancomycine dans le traitement des infections à Staphylococcus aureus ?. Méd Mal Infect 2006, 36:439-442. 10.1016/j.medmal.2006.07.016.
8. Glycopeptides. Maladies infectieuses et tropicales 2005, 95-97. Vivactis Plus, Paris. 19th ed. E. Pilly (Ed.).
9. Société de pathologie infectieuse de langue française. Les méningites purulentes communautaires. 9e Conférence de consensus en thérapeutique anti-infectieuse. Med Mal Infect 1996, 26:952-973. 10.1016/S0399-077X(96)80004-7.
10. Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45:2460-2467. 10.1128/AAC.45.9.2460-2467.2001.
11. Vuagnat A., Stern R., Lotthe A., Schuhmacher H., Duong M., Hoffmeyer P., et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004, 29:351-357. 10.1111/j.1365-2710.2004.00572.x.
12. Bernard E., Perbost I., Carles M., Michiels A., Carsenti-Etesse H., Chichmanian R.M., et al. Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infections. Clin Microbiol Infect 1997, 3:440-446. 10.1111/j.1469-0691.1997.tb00280.x.
13. Harding I., MacGowan A.P., White L.O., Darley E.S., Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000, 45:835-841.
14. Georges H., Leroy O., Alfandari S., Guery B., Roussel-Delvallez M., Dhennain C., et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997, 16:385-388.
15. Owens R.C., Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis 2006, 42(Suppl. 4):S173-S181. 10.1086/500664.
16. Bianco A., Rizza P., Scaramuzza G., Pavia M. Appropriateness of glycopeptide use in a hospital in Italy. Int J Antimicrob Agents 2006, 27:113-119. 10.1016/j.ijantimicag.2005.10.004.
17. Drinkovic D., Taylor S.L., Pottumarthy S., Morris A.J. Prospective vancomycin audit in Auckland healthcare hospitals. N Z Med J 1999, 112:336-339.
18. Evans M.E., Kortas K.J. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996, 17:356-359.
19. Levent T., Lambiotte F., Vasseur M., De Zorzi S., Gosteau L., Paradis P. Évaluation prospective de la prescription des glycopeptides dans un hôpital général. Med Mal Infect 2005, 35:411-416. 10.1016/j.medmal.2005.06.005.
20. You J.H., Lyon D.J., Lee B.S., Kwan S.M., Tang H.Y. Vancomycin utilization at a teaching hospital in Hong Kong. Am J Health Syst Pharm 2001, 58:2167-2169.
21. Byl B., Clevenbergh P., Jacobs F., Struelens M.J., Zech F., Kentos A., et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999, 29:60-66. 10.1086/520182.
22. Dellit T.H., Owens R.C., McGowan J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177. 10.1086/510393.
23. Lowdin E., Odenholt I., Cars O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998, 42:2739-2744.
24. Knudsen J.D., Fuursted K., Raber S., Espersen F., Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000, 44:1247-1254.
25. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., Falagas M.E. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5:581-589. 10.1016/S1473-3099(05)70218-8.
26. López P., Gavaldà J., Martin M.T., Almirante B., Gomis X., Azuaje C., et al. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob Agents Chemother 2001, 45:1387-1393. 10.1128/AAC.45.5.1387-1393.2001.
27. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402. 10.1128/JCM.42.6.2398-2402.2004.
28. Mohr J.F., Murray B.E. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infec Dis 2007, 44:1536-1542. 10.1086/518451.
29. Freeman C.D., Quintiliani R., Nightingale C.H. Vancomycin therapeutic drug monitoring: is it necessary?. Ann Pharmacother 1993, 27:594-598.
30. Jeffres M.N., Isakow W., Doherty J.A., McKinnon P.S., Ritchie D.J., Micek S.T., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130:947-955. 10.1378/chest.130.4.947.
31. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
32. Seetulsingh P., Collier S. An audit of teicoplanin use in a district general hospital. J Hosp Infect 2006, 66:195-196. 10.1016/j.jhin.2006.05.007.
33. Kollef M.H. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001, 5:189-195. 10.1186/cc1022.
34. Zahar J.R., Rioux C., Girou E., Hulin A., Sauve C., Bernier-Combes A., et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother 2006, 58:651-656. 10.1093/jac/dkl288.
35. Fowler V.G., Sanders L.L., Sexton D.J., Kong L., Marr K.A., Gopal A.K., et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998, 27:478-486.